APx Acquisition Corp I
APXI

About: APx Acquisition Corp I is a newly incorporated blank check company.

Employees: 2

Financials Blank Checks

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

2% more capital invested

Capital invested by funds: $58.7M [Q1] → $59.8M (+$1.16M) [Q2]

0.19% more ownership

Funds ownership: 51.86% [Q1] → 52.05% (+0.19%) [Q2]

0% more funds holding

Funds holding: 22 [Q1] → 22 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

57% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 7

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for APXI.

See Analyst Rankings

Financial journalist opinion

APX Acquisition Corp. I Reports 10-K Delinquency Notice

NASHVILLE, Tenn. , June 5, 2024 /PRNewswire/ -- APX Acquisition Corp. I (NASDAQ: APXI ) ("Company"), a publicly traded special purpose acquisition company, today announced that it received a deficiency letter (the "Letter") on May 30, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq").

APX Acquisition Corp. I Reports 10-K Delinquency Notice

APx Acquisition Corp. I, OmnigenicsAI Corp and MultiplAI Health Ltd enter into Business Combination Agreement to create a global AI-driven genomics platform

NASHVILLE, Tenn. , March 26, 2024 /PRNewswire/ -- APx Acquisition Corp. I (NASDAQ: APXI) ("APx"), a publicly traded special purpose acquisition company, OmnigenicsAI Corp ("OmnigenicsAI"), a precision medicine company incubated by Bioceres Group PLC, and MultiplAI Health Ltd ("MultiplAI"), a UK-based AI-enabled preventive medicine company, have entered into a definitive Business Combination Agreement ("BCA") that, upon closing, would result in OmnigenicsAI becoming a publicly listed company.

APx Acquisition Corp. I, OmnigenicsAI Corp and MultiplAI Health Ltd enter into Business Combination Agreement to create a global AI-driven genomics platform

APX Acquisition Corp. I receives Nasdaq notice on late filing of its Form 10-Q

NASHVILLE, Tenn., Dec. 28, 2023 /PRNewswire/ -- APX Acquisition Corp. I (NASDAQ: APXI) ("Company"), a publicly traded special purpose acquisition company, today announced that it received a deficiency letter (the "Letter") on December 21, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq").

APX Acquisition Corp. I receives Nasdaq notice on late filing of its Form 10-Q

APX Acquisition Corp. I & Bioceres Group Announce Letter of Intent for a Business Combination with a Precision Medicine Diagnostic and Wellness Services Company

NASHVILLE, Tenn. , Dec. 1, 2023 /PRNewswire/ -- APX Acquisition Corp. I (NASDAQ: APXI) ("Company"), a publicly traded special purpose acquisition company, announced today that it has signed a non-binding letter of intent ("LOI") for a proposed business combination (the "Business Combination") with a precision medicine company that offers genomic diagnostic tests in clinical genomics, oncology, human microbiome and reproductive genomics, as well as a digital nutrition-based DNA and gut microbiome wellness service that promotes wellbeing and prevents disease ("Target"), that would result in a public listing of the combined company upon completion of the proposed Business Combination.

APX Acquisition Corp. I & Bioceres Group Announce Letter of Intent for a Business Combination with a Precision Medicine Diagnostic and Wellness Services Company

See News Rankings